Abdullahi Auwal, Candan Sevim Acaroz, Soysal Tomruk Melda, Elibol Nuray, Dada Olumide, Truijen Steven, Saeys Wim
Department of Physiotherapy, Bayero University, Kano, Nigeria.
Department of Physiotherapy and Rehabilitation Sciences, University of Antwerp, Antwerp, Belgium.
Front Neurol. 2021 Jan 13;11:566308. doi: 10.3389/fneur.2020.566308. eCollection 2020.
There is emerging evidence that Guillain-Barré syndrome (GBS) may be associated with coronavirus disease 2019 (COVID-19) infection. The aim of this review was to investigate the strength of the evidence. The review was registered in PROSPERO (CDR42020184822). Three electronic databases, MEDLINE, PubMed, and Web of Science, and three preprint servers, MedRvix, ChemRvix, and BioRvix, were searched from December 2019 to 24th September 2020. Studies were included if they were on COVID-19 and of any design. Articles that are reviews or opinion were excluded. The selection process was carried out using EndNote and Rayyan software. The main outcomes in the study were study design, sample size, sex, age, overall GBS symptoms, other COVID-19 symptoms, comorbidity, timing between infection and the onset of neurological symptoms, CT, MRI, and EMG results. Methodological quality of the studies was assessed using the McMaster Critical Review Form. The collected data was analyzed using qualitative synthesis. Fifty-one high-quality studies (mostly) consisting of 83 patients were included in the study. All of the patients (except in a very few) in the included studies had confirmed diagnosis of COVID-19. Similarly, the diagnosis of GBS was based on standard clinical, electrophysiological, and cerebrospinal fluid (CSF) criteria. GBS may be associated with COVID-19, and therefore, testing for COVID-19 is recommended in patients presenting with GBS during this pandemic.
越来越多的证据表明，吉兰-巴雷综合征（GBS）可能与2019冠状病毒病（COVID-19）感染有关。本综述的目的是调查证据的力度。该综述已在国际前瞻性系统评价注册库（PROSPERO，注册号：CDR42020184822）登记。从2019年12月至2020年9月24日，检索了三个电子数据库，即医学期刊数据库（MEDLINE）、美国国立医学图书馆生物医学信息检索系统（PubMed）和科学引文索引数据库（Web of Science），以及三个预印本服务器，即医学预印本平台（MedRvix）、化学预印本平台（ChemRvix）和生物学预印本平台（BioRvix）。纳入的研究需是关于COVID-19且采用任何设计类型的研究。排除综述或观点类文章。使用EndNote和Rayyan软件进行筛选过程。研究的主要结局包括研究设计、样本量、性别、年龄、GBS总体症状、其他COVID-19症状、合并症、感染与神经症状发作之间的时间、计算机断层扫描（CT）、磁共振成像（MRI）和肌电图（EMG）结果。使用麦克马斯特批判性评价表评估研究的方法学质量。采用定性综合分析收集的数据。该研究纳入了51项高质量研究（大多数研究），共83例患者。纳入研究中的所有患者（极少数除外）均确诊为COVID-19。同样，GBS的诊断基于标准的临床、电生理和脑脊液（CSF）标准。GBS可能与COVID-19有关，因此，在本次大流行期间，对于出现GBS的患者建议进行COVID-19检测。
